Compare Enphase Energy Inc (ENPH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Novartis AG — how do they compare? Enphase Energy Inc trades at $42.4 (market cap $5.41B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 55.1× Enphase Energy Inc's market cap, and Novartis AG pays a 3.02% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| ENPH | NVS | |
|---|---|---|
Market Cap | $5.41B | $298.18B |
Sector | Technology | Health |
52-Week High | $72.33 | $168.62 |
52-Week Low | $26.12 | $119.31 |
Enterprise Value | $5.05B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $41.87, up 5.55% with bullish technical signals and mixed quarterly earnings. The company reported Q2 2026 EPS of $0.46, missing expectations, while revenue declined 19.6% year-over-year. Recent product expansions in battery systems and U.S. manufacturing commitments provide growth catalysts, though residential solar demand remains volatile. Valuation metrics show a P/E of 41.46 and P/S of 4.2, reflecting premium pricing amid earnings normalization.
Outlook remains cautiously optimistic with analyst consensus price target of $45.37 offering 8% upside potential. Key opportunities include European storage growth and AI data center initiatives, while risks center on U.S. demand weakness and competitive pressures. The stock faces near-term resistance at $43-$45 levels with institutional ownership showing mixed positioning through recent filings.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
